Corvus Pharmaceuticals Inc Cash Flow Conversion Efficiency
Corvus Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has a cash flow conversion efficiency ratio of -0.068x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.40 Million) by net assets ($225.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Corvus Pharmaceuticals Inc (2014–2025)
Cash flow conversion efficiency of Corvus Pharmaceuticals Inc from 2014 to 2025. This chart illustrates how Corvus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CRVS stock price for real-time trading data and today's change.
Corvus Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Corvus Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Corvus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see CRVS market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing eGOVA
SHE:300075
|
-0.007x |
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
-0.071x |
|
Hengtong Logistic Co Ltd
SHG:603223
|
-0.077x |
|
GL Events SA
PA:GLO
|
0.162x |
|
Nanjing Red Sun Co Ltd
SHE:000525
|
0.021x |
|
MBK Public Company Limited
BK:MBK
|
0.059x |
|
Ryerson Holding Corp
NYSE:RYI
|
0.148x |
|
Direcional Engenharia S.A.
SA:DIRR3
|
0.055x |
Annual Cash Flow Conversion Efficiency for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Corvus Pharmaceuticals Inc from 2014 to 2025. Review CRVS free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.20 Million | $-32.80 Million | -0.536x | +31.36% |
| 2024-12-31 | $32.57 Million | $-25.42 Million | -0.781x | -26.17% |
| 2023-12-31 | $38.68 Million | $-23.93 Million | -0.619x | -28.48% |
| 2022-12-31 | $56.12 Million | $-27.02 Million | -0.482x | -27.44% |
| 2021-12-31 | $97.16 Million | $-36.72 Million | -0.378x | +21.61% |
| 2020-12-31 | $72.15 Million | $-34.78 Million | -0.482x | +8.15% |
| 2019-12-31 | $71.11 Million | $-37.32 Million | -0.525x | -41.28% |
| 2018-12-31 | $110.34 Million | $-40.99 Million | -0.371x | +31.80% |
| 2017-12-31 | $84.83 Million | $-46.21 Million | -0.545x | -159.68% |
| 2016-12-31 | $132.80 Million | $-27.86 Million | -0.210x | -157.59% |
| 2015-12-31 | $-31.10 Million | $-11.33 Million | 0.364x | -44.70% |
| 2014-12-31 | $-159.00K | $-104.73K | 0.659x | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more